科源制药
(301281)
| 流通市值：19.33亿 | | | 总市值：30.41亿 |
| 流通股本：6885.20万 | | | 总股本：1.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 330,879,995.68 | 237,142,859.74 | 146,276,963.82 | 447,583,620.32 |
| 营业收入 | 330,879,995.68 | 237,142,859.74 | 146,276,963.82 | 447,583,620.32 |
| 二、营业总成本 | 303,707,035.89 | 211,807,312.62 | 124,459,548.73 | 381,057,260.02 |
| 营业成本 | 200,947,386.28 | 140,211,296.13 | 85,598,444.16 | 236,091,946.9 |
| 税金及附加 | 5,543,609.05 | 4,508,633.81 | 1,566,297.03 | 4,843,312.46 |
| 销售费用 | 49,859,949.6 | 34,812,126.39 | 20,930,375.42 | 63,399,885.46 |
| 管理费用 | 27,956,440.65 | 18,408,211.01 | 8,510,046.78 | 37,710,815.03 |
| 研发费用 | 22,354,267.62 | 16,083,468.01 | 8,784,714.8 | 43,859,260.03 |
| 财务费用 | -2,954,617.31 | -2,216,422.73 | -930,329.46 | -4,847,959.86 |
| 其中:利息收入 | 3,241,989.83 | 2,274,302.61 | 1,276,190.62 | 3,769,045.21 |
| 加:公允价值变动收益 | 757,130.57 | 370,109.59 | 1,017,373.16 | 543,183.1 |
| 加:投资收益 | 7,250,793.55 | 5,779,909.8 | 540,743.96 | 12,201,059.45 |
| 资产处置收益 | 77,957.39 | 77,957.39 | - | 345,993.55 |
| 资产减值损失(新) | -3,568,389.39 | -827,106.59 | -2,840.7 | -3,377,172.45 |
| 信用减值损失(新) | 229,847.8 | -307,503.44 | -1,703,932.59 | -115,012.21 |
| 其他收益 | 13,859,141.13 | 12,039,029.25 | 2,759,649.86 | 3,992,164.91 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 45,779,440.84 | 42,467,943.12 | 24,428,408.78 | 80,116,576.65 |
| 加:营业外收入 | 59,028.52 | 59,027.41 | - | 313,368.13 |
| 减:营业外支出 | 2,921,327.9 | 1,789,140.57 | 1,199,361.42 | 694,887.06 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,917,141.46 | 40,737,829.96 | 23,229,047.36 | 79,735,057.72 |
| 减:所得税费用 | 3,361,680.37 | 4,710,645.84 | 1,705,284.3 | 2,695,618.57 |
| 六、净利润 | 39,555,461.09 | 36,027,184.12 | 21,523,763.06 | 77,039,439.15 |
| 持续经营净利润 | 39,555,461.09 | 36,027,184.12 | 21,523,763.06 | 77,039,439.15 |
| 归属于母公司股东的净利润 | 39,683,076.25 | 36,091,102 | 21,532,537.03 | 77,039,439.15 |
| 少数股东损益 | -127,615.16 | -63,917.88 | -8,773.97 | - |
| (一)基本每股收益 | 0.37 | 0.33 | 0.2 | 0.76 |
| (二)稀释每股收益 | 0.37 | 0.33 | 0.2 | 0.76 |
| 九、综合收益总额 | 39,555,461.09 | 36,027,184.12 | 21,523,763.06 | 77,039,439.15 |
| 归属于母公司股东的综合收益总额 | 39,683,076.25 | 36,091,102 | 21,532,537.03 | 77,039,439.15 |
| 归属于少数股东的综合收益总额 | -127,615.16 | -63,917.88 | -8,773.97 | - |
| 公告日期 | 2024-10-25 | 2024-08-20 | 2024-04-22 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |